Integrated BRAC*Analysis*® to Include BART™

NCCN and Medicare Guideline Update on BART:

The **B**RAC**A**nalysis® Large **R**earrangement **T**est (BART™) provides a way to detect large genomic rearrangements in both *BRCA1* and *BRCA2* that are not identified as part of the BRAC**A**nalysis sequencing test. Large rearrangement mutations account for 6-10%¹ of all Hereditary Breast and Ovarian Cancer (HBOC) mutations identified.


The National Comprehensive Cancer Network² (NCCN) has updated their HBOC guidelines to support the inclusion of large rearrangement testing (BART) for all patients undergoing genetic testing for the BRCA1 and BRCA2 genes.

Many large payors, including **Medicare**, have responded to the NCCN guideline change and will now include coverage of large rearrangement analysis as part of *BRCA1* and *BRCA2* testing for patients that meet their medical coverage criteria.

How is BART ordered?

As recommended in the NCCN guidelines, Myriad's standard offering for HBOC will shift to "Integrated BRACAnalysis" which will now include BART as part of *BRCA1* and *BRCA2* gene analysis. This test can be ordered on our new Test Request Form (TRF) (with a date in lower left corner of 08-12) by checking the "Integrated BRACAnalysis" box. Updated test kits that include the new TRF will be available beginning January 1, 2013.

You are also able to order Integrated BRACAnalysis testing on older TRF versions, but you must select both the "Comprehensive BRACAnalysis" and "BART" boxes, or select "Comprehensive BRACAnalysis" and write in "BART" on the "Other" line.



Will insurance cover the cost of BART?

Medicare as well as many large national and regional insurance companies now include coverage for BART as part of *BRCA1* and *BRCA2* analysis. Myriad will continue to work with the remaining insurers to determine coverage and update medical policy to reflect the new NCCN guidelines. For patients who meet the Myriad Financial Assistance Program criteria for BRCA testing, BART will be included as part of their testing. Additionally, any patient who receives a bill and has concerns can call the telephone number on the invoice. We guarantee that we will work together with the patient to reach a solution.

For more information and answers to frequently asked questions about BART go to www.myriadpro.com/BRAC_BART



Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, Utah 84108 www.myriadpro.com



- 1. Judkins T, et al. Clinical Significance of Large Rearrangements in BRCA1 and BRCA2. Cancer 2012 (Epub ahead of print).
- 2. Accessed at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp